Modality
Vaccine
MOA
CD3xCD20
Target
Tau
Pathway
Neuroinflam
NSCLC
Development Pipeline
Preclinical
~Jan 2019
→ ~Apr 2020
Phase 1
~Jul 2020
→ ~Oct 2021
Phase 2
Jan 2022
→ Jul 2030
Phase 2Current
NCT05729045
2,382 pts·NSCLC
2022-06→2030-07·Terminated
NCT05285525
1,937 pts·NSCLC
2022-01→TBD·Not yet recruiting
4,319 total pts1 indication
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2030-07-234.3y awayPh2 Data· NSCLC
Trial Timeline
2022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3
P2
Not yet…
P2
Termina…
Catalysts
Ph2 Data
2030-07-23 · 4.3y away
NSCLC
TerminatedNot yet recruiting|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT05729045 | Phase 2 | NSCLC | Terminated | 2382 | UPCR |
| NCT05285525 | Phase 2 | NSCLC | Not yet recr... | 1937 | Biomarker |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| LLY-1184 | Eli Lilly | NDA/BLA | C5 | |
| Zanuderotide | Novartis | Phase 1/2 | VEGF | |
| NVO-1361 | Novo Nordisk | Phase 3 | CD38 | |
| Zorizanubrutinib | Novo Nordisk | Phase 1 | BTK | |
| NVO-9087 | Novo Nordisk | Phase 1/2 | Tau | |
| Tezecilimab | Takeda | NDA/BLA | Tau | |
| TAK-8262 | Takeda | NDA/BLA | Tau | |
| Pexamavacamten | Daiichi Sankyo | NDA/BLA | TIGIT | |
| ITC-1028 | Intra-Cellular | Phase 2 | BCMA | |
| Cevizasiran | Acadia Pharma | Phase 1/2 | GPRC5D |